Home/ Stocks/ OCGN

Ocugen, Inc. Common Stock

OCGN XNAS

$1.39 +0.02 (+1.30%) ▲ 15-min delayed

Open

$1.41

High

$1.42

Low

$1.37

Volume

2.45M

Market Cap

$471.36M

About Ocugen, Inc. Common Stock

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 116 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$1.49M	$-24,877,000	$-0.07
Q1 2026	$1.53M	$-19,177,000	$-0.06
FY 2025	$4.41M	$-67,846,000	N/A
Q3 2025	$1.75M	$-20,051,000	N/A

Related Market News

No specific coverage for OCGN yet. Check out our latest market news or earnings calendar.

Get OCGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Ocugen, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.